Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...

Weihai Bank will raise about 1 billion yuan by selling new shares to an investment vehicle owned by municipal organizations ...

And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...

Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

RBI plans to add about $32 billion of liquidity to the banking system over the next month to ensure enough cash is available ...

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...

The Reserve Bank of India will infuse about $32 billion worth of rupee liquidity into the banking system over the next month ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...